OncoCyte Corporation (OCX)

NASDAQ: OCX · IEX Real-Time Price · USD
0.950
-0.037 (-3.72%)
Aug 8, 2022 4:00 PM EDT - Market closed
-3.72%
Market Cap 119.06M
Revenue (ttm) 8.03M
Net Income (ttm) -70.47M
Shares Out 125.37M
EPS (ttm) -0.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 193,007
Open 1.030
Previous Close 0.986
Day's Range 0.905 - 1.030
52-Week Range 0.805 - 5.480
Beta 1.76
Analysts Buy
Price Target 3.21 (+238.0%)
Earnings Date Aug 10, 2022

About OCX

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collab... [Read more...]

Industry Biotechnology
Founded 2009
Employees 110
Stock Exchange NASDAQ
Ticker Symbol OCX
Full Company Profile

Financial Performance

In 2021, OncoCyte's revenue was $7.73 million, an increase of 535.44% compared to the previous year's $1.22 million. Losses were -$64.10 million, 114.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for OCX stock is "Buy." The 12-month stock price forecast is 3.21, which is an increase of 238.00% from the latest price.

Price Target
$3.21
(238.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oncocyte to Participate at Upcoming Investor Conferences

IRVINE, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that...

Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective ...

IRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights tha...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating OncoCyte Corporation for Potential Breaches of Fiduciary ...

NEW YORK , July 28, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim i...

Oncocyte to Announce Second Quarter 2022 Financial Results

IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that...

OncoCyte (OCX) Upgraded to Buy: Here's What You Should Know

OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice

IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights t...

Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunoth...

DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need

OncoCyte (OCX) Reports Q1 Loss, Lags Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of 15.38% and 16.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Oncocyte Completes Validation of TheraSure™ Transplant Monitor Test

Digital PCR format allows for rapid turnaround time to facilitate fast and accurate post-transplant treatment decisions Digital PCR format allows for rapid turnaround time to facilitate fast and accurat...

Oncocyte to Announce First Quarter 2022 Financial Results

IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights tha...

Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™

Data points to accuracy of IO Score and provides grounds for its further use to evaluate response to immune checkpoint therapies for patients with colorectal, gastric and breast cancers Data points to a...

Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today the pricing of an underwritten public offering of 26,266,417 shares ...

Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), announced today that it has commenced an underwritten public offering of shares of i...

Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferr...

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), (“Oncocyte” or the “Company”), a precision diagnostics company with the mission to improve patient outcomes by prov...

Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder ...

Poster outlines data showing Oncocyte's DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer

OncoCyte (OCX) Q4 Earnings Match Estimates, Revenues Lag (Revised)

OncoCyte (OCX) delivered earnings and revenue surprises of 0% and -17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q4 Loss, Lags Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of -20% and 17.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision...

Collaboration extends global reach for Thermo Fisher's rapid next-generation sequencing technology

Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte's DetermaIO™ Clinical ...

Data supports the use of DetermaIO as a pan-cancer diagnostic tool, now addressing an unmet need for patients with triple negative breast cancer, the most aggressive type of breast cancer

Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer a...

Spotlight poster presentation indicates DetermaIO assay and algorithm is robust across multiple diagnostic platforms, confirms that test predicts response to immunotherapy (atezolizumab) benefit

OncoCyte (OCX) Reports Q3 Loss, Lags Revenue Estimates

OncoCyte (OCX) delivered earnings and revenue surprises of -57.14% and -69.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test

DetermaIO is the first and only immunotherapy clinical test that comprehensively assesses the tumor microenvironment

Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Ea...

U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe

Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th

IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insig...